Certolizumab pegol (n=68) | Etanercept (n=30) | Adalimumab (n=25) | Infliximab (n=14) | |
Stop time point as recommended by EULAR-PtC, weeks | N/A | GA 30–32 | GA 20 | GA 20 |
Gestational age (GA) at time of stopping TNFi, weeks | 37.0 (34.1–38.1) | 25.0 (17.9–28.0) | 19.0 (12.4–19.9) | 18.4 (14.0–20.1) |
Stopped before recommended GA, n (%) | N/A | 29 (96.7%) | 20 (80.0%) | 10 (71.4%) |
No measurable TNFi in cord blood, n (%) | 64 (94.1%) | 30 (100%) | 13 (52.0%) | 6 (42.8%) |
Measurable TNFi in cord blood, n (%) | 4 (5.9%) | 0 (0%) | 12 (48.0%) | 8 (57.1%) |
Maternal concentration of TNFi in the 1st trimester, µg/mL | 24.6 (19.0–31.0) | 2.1 (0.8–2.5) | 8.2 (1.5–10.0) | 14.0 (8.0–21.0) |
Maternal concentration of TNFi in the 2nd trimester, µg/mL | 22.5 (13.0–30.72) | 1.4 (0.9–2.7) | 6.0 (4.5–7.5) | 6.4 (4.2–20.0) |
Maternal concentration of TNFi in the 3rd trimester, µg/mL | 20.5 (13.0–29.6) | 0.2 (0.2–0.7) | 0.9 (0.1–1.4) | 1.4 (0.1–1.9) |
Concentration of TNFi in the cord blood if measurable, µg/mL | 0.3 (0.2–1.3) | – | 0.5 (0.2–0.7) | 0.4 (0.1–1.2) |
Concentration ratio cord blood to maternal blood* | 0.010 (0.007–0.066) | – | 0.062 (0.018–0.15) | 0.012 (0.006–0.081) |
*Concentration ratios of cord blood to maternal blood were calculated with the maternal concentrations during active use of TNFi (trimester 3 for certolizumab pegol and trimester 1 for adalimumab and infliximab).
EULAR, European League Against Rheumatism; PtC, points to consider; TNF, tumour necrosis factor .